Skip to main content
. 2018 Dec 12;14(1):75–83. doi: 10.1007/s11523-018-0612-z

Table 3.

Tumor response to osimertinib

Afatinib treatment line
Any (N = 49) First (n = 36)
Response, n (%)
 Overall 37 (75.5) 28 (77.8)
  Complete 11 (22.4) 7 (19.4)
  Partial 26 (53.1) 21 (58.3)
 Stable disease 3 (6.1) 2 (5.6)
 Progressive disease 6 (12.2) 4 (11.1)
 Not evaluable 3 (6.1) 2 (5.6)